Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CCL2 | P13500 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958554 | 0.74 | BRD4 (0.37) | BRD4CCL2HTR2AATM | |
| SCHEMBL17234511 | 0.72 | BRD4 (0.34) | BRD4CCL2ATM | |
| SCHEMBL11348748 | 0.72 | BRD4 (0.41) | BRD4CCL2HTR2AATM | |
| SCHEMBL20506900 | 0.70 | ATM (0.38) | BRD4CCL2HTR2AATM | |
| SCHEMBL19637760 | 0.69 | BRD4 (0.32) | BRD4CCL2 | |
| SCHEMBL20506906 | 0.69 | ATM (0.40) | BRD4CCL2ATM | |
| SCHEMBL418352 | 0.68 | BRD4 (0.38) | BRD4CCL2HTR2AATM | |
| SCHEMBL19452304 | 0.67 | BRD4 (0.35) | BRD4CCL2ATM | |
| SCHEMBL18645092 | 0.66 | BRD4 (0.34) | BRD4CCL2 | |
| SCHEMBL17284105 | 0.66 | BRD4 (0.36) | BRD4CCL2HTR2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427460-B1 | NOVEL ISOQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-26 | — | — | EP | claimed |
| EP-2427460-A1 | NOVEL ISOQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | claimed |
| WO-2010128061-A1 | NOVEL ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
| WO-2010128061-A1 | NOVEL ISOQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, LDLR, PCSK9 | BRD4 3413/4885CCL2 3063/4885HTR2A 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.